Track the TPD clinical trial and drug landscape with Beacon TPD
What we cover
Beacon TPD covers trial and drug records for clinical,
preclinical, approved and discontinued therapeutics
involved in targeted protein degradation and induced
proximity. The database covers:
- Bivalent Degraders
- Monovalent Degraders
- Induced Proximity Assets
- Proteasome Inhibitors
- DUB Inhibitors
- E1/E2/E3 Modulators
- Other comparable modalities
New data expansion: Deals and Companies. Gain unparalleled access to in-depth company profiles and the latest commercial deals. Monitor your competitors and opportunities as well as benchmark deals and evaluate potential partners. Learn more about Deals and Companies data by downloading the factsheet.
How Beacon helps
Here are some examples of how Beacon TPD can accelerate your research programs:
- Search for TPD drugs across all stages of development so you can stay on top of new approaches in drug design.
- Drastically reduce manual research time with our database solution which allows you to rapidly assemble data for analysis based on targets, ligands, ligases and much more.
- Real time updates to help you keep track of new players, new assets and entries into the clinic.
How Beacon TPD works
Search the trial and drug landscape by target, ligands and effectors alongside
other search criteria to instantly extract
the data points you need to conduct
more complex analysis.
Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the TPD space.
How we target the data
We house all publicly available sources of data updated within 24 – 48 hours of publication proactively. Our sources cover (but are not limited to):
- Clinical trials registries
- Scientific journals and publications
- Company reports and presentations
- Press releases
- Conference reports and abstracts
- Government and regulatory organizations
- Newspapers and other media
Our TPD Expert
Katie Spooner, Msc, is the lead research analyst for Beacon TPD.
Sign up to her weekly newsletter to uncover the latest insights into the TPD landscape using data from Beacon.
Other Beacon Solutions
Covering all Antibody Drug Conjugates (ADCs), Small Molecule Drug Conjugates (SMDCs), Protein Drug Conjugates (PDCs), Immunotoxins and more
Covering all Bi- and Multi-Specific Antibodies, Antibody Fragments, Augmented Antibodies and more
Beacon Cancer Vaccine provides the solution you need to master the prophylactic and therapeutic cancer vaccines field.
Covering all genetically and non-genetically engineered allogeneic and autologous cell-based therapies across all disease indications
Covering all Immune Checkpoint Combination Trials and Immune Checkpoint Modulators in development across 27 different checkpoint targets
Covering all cytokines and drugs that target a cytokine or its immediate receptor belonging to the Interleukins, Interferons, Colony-stimulating factors, Transforming growth factor β, Tumour necrosis factor and Chemokines families.
Beacon DDR steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the DDR field.
Covering all therapeutics aimed at treating immune-mediated diseases – Beacon Immune Tolerance provides drug developers with detailed views of the expanding immune tolerance landscape.
From gene-editing technologies, novel delivery systems, and a variety of genetic materials being used- Beacon Gene Therapy steps into the field to give drug developers a precise and detailed view of how the gene therapy landscape looks.
Covering all pharmaceutical grade microbiome-based therapeutics across all disease indications – Beacon Microbiome provides drug developers with detailed views of the expanding microbiome landscape.
From capturing viral family and strains to understanding any genetic modifications – Beacon Oncolytic Viruses steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the Oncolytic Virus field.
Covering Oligonucleotide-based, mRNA-Based, Ribozyme, and gRNA-Mediated Gene Editing therapies, as well as RNA-Targeted Small Molecules – Beacon RNA covers all disease indications and many modalities to provide a detailed landscape of the RNA space.
Any questions? Contact us
To learn more about how we can tailor Beacon TPD to help you, get in touch with our sales team
Thomas Vickers and Jordan Rumbelow
TPD Account Managers
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.